The ATB200-02 study is an international, multi-center, study in adult subjects with Pompe disease.
The purpose of this study is to find out if AT2221 can be safely used with ATB200 and will increase ATB200 in the bloodstream.
Clinical Trial Overview
The purpose of this study is to find out if the co-administration of investigational new drugs ATB200 administered intravenously (IV) and AT2221 administered orally is safe in adults with Pompe disease. To learn more about this clinical trial please visit: www.clinicaltrials.gov.
Participant Criteria
The ATB200-02 Study is open to males and females aged 18-65 with Pompe disease, who are Enzyme Replacement Therapy (ERT)-experienced subjects (ambulatory) on a stable ERT dose and regimen, ERT-experienced subjects (non-ambulatory) or ERT-Naïve subjects (ambulatory).
Study Locations
The ATB200-02 Study is being conducted at sites in countries around the world, including sites in Europe, Australia and the United States. In the United States, the study will be conducted in various states from coast-to-coast. Additional locations/sites are continually being explored. Check back periodically for updated site information.
